Under construction – not a live service
Sign in
Taking peopleNo phase

Risk factors for ganciclovir-resistant cytomegalovirus after organ or stem cell transplant

Looks at why cytomegalovirus stops responding to ganciclovir in transplant recipients.

Key facts

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Where
Lausanne and Zurich, SwitzerlandSee the 2 sitesAlso in 8 other countries, 21 sites
Trial code
Registry title
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
Status
Recruiting
People taking part
100 people, planned
Started
19 Jun 2023
Expected to end
28 Feb 2028
Type of study
Observational
Record updated
15 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had a solid organ transplant or a blood stem cell transplant and then got a cytomegalovirus (CMV) infection treated with GC/VGC. It looks back at existing records.

Age
18 years and older
Sex
All sexes
Disease stage
CMV infection after a solid organ transplant (SOT) or a blood stem cell transplant (HSCT)
Earlier treatment
The CMV infection must have been treated with GC/VGC (ganciclovir or valganciclovir).

Main reasons for not taking part

  • No clinical or lab data on the type of CMV event
  • No record of whether donor and recipient blood tests for CMV differed at transplant
  • Type of transplant (SOT or HSCT) not known
  • No record of patient and transplant outcome at 30, 60 or 90 days after the CMV diagnosis

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
  • Ability to understand the purpose of the study and provide signed and dated informed consent

Who cannot take part

  • Lack of the serological mismatch at transplantation
  • Lack of clinical and/or laboratory data regarding the type of CMV event
  • Lack of the type of SOT or HSCT
  • Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis

Where in Switzerland

Also in 8 other countries, 21 sites

  • Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandContact: Manuel OriolNot yet recruiting
  • University Hospital ZurichZurich, SwitzerlandContact: Nicolas MuellerNot yet recruiting

About the trial

What the trial wants to find out

The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

The group in the trial

  • Solid Organ Transplant and Hematopoietic Stem Cell Transplant patients

    Solid Organ Transplant (SOT) and Hematopoietic Stem Cell Transplant (HSCT) patients with Ganciclovir Resistant or Refractory Cytomegalovirus infection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
Plain-language title
Risk factors for ganciclovir-resistant cytomegalovirus after organ or stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 June 2026